-
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
25 Aug 2023 05:20 GMT
… Chinese leading biopharmaceutical company 3SBio (01530.HK) today … patients." About 3SBio Inc. 3SBio is a leading … several therapeutic areas such as nephrology, oncology, autoimmune diseases, … China. Please visit www.3sbio.com for additional information …
-
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
22 Mar 2023 04:45 GMT
… millions of patients with nephrology and liver diseases.
3SBio will continue to … fields of its strength, namely, nephrology, autoimmune diseases, hair and skin … several therapeutic areas such as nephrology, oncology, autoimmune diseases, ophthalmology and …
-
Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28
14 Dec 2021 08:30 GMT
Numab Therapeutics AG (Numab) and 3SBio Inc. (“3SBio”, HKEX:1530) announced today that … www.numab.com.
About 3SBio Inc.
3SBio is a fully integrated biotechnology … , auto-immune diseases, nephrology, metabolic diseases and dermatology. 3SBio is focusing on …
-
TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China
26 Aug 2020 09:40 GMT
… and scalable in manufacturing. About 3SBio 3SBio is a fully-integrated biotechnology … auto-immune diseases, nephrology, metabolic diseases and dermatology. 3SBio is focusing on … 30 product candidates under development. 3SBio's manufacturing capabilities …
-
TLC and 3SBio Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China
04 Mar 2019 02:57 GMT
… biopharmaceutical company specializing in oncology, nephrology, auto immune diseases, metabolic … Corporate Governance Evaluations. About 3SBio 3SBio is a fully-integrated … -immune diseases, nephrology, metabolic diseases and dermatology. 3SBio is focusing on …
-
3SBio enters agreement with Samsung Bioepis for clinical development of multiple biosimilar candidates
08 Jan 2019 07:22 GMT
… and chief executive officer of 3SBio. "3SBio will continue to strengthen … ' proven development platform with 3SBio's strong commercialization platform … , auto-immune diseases, nephrology, metabolic diseases and dermatology. 3SBio is focusing on …
-
Samsung Bioepis Partners with 3SBio to Expand Biosimilar Business into China
07 Jan 2019 11:00 GMT
… million doses
administered.
About 3SBio Inc.
3SBio is a fully-integrated … auto-immune
diseases, nephrology, metabolic diseases and dermatology. 3SBio is
focused on …
products candidates under development. 3SBio’s manufacturing
capabilities include recombinant …
-
3SBio : Accelerates Expansion of its Global Biologics Platform by Acquiring the Canadian Biomanufacturing Business of Therapure
18 Sep 2017 07:28 GMT
… clients.'
About 3SBio Inc.
3SBio Inc. is a fully … auto-immune diseases and nephrology. Its main products include … candidates under development. 3SBio manufacturing capabilities include recombinant … Shenzhen and Como, Italy. 3SBio Inc. is actively pursuing …
-
Chinese biopharma 3SBio in $290 million deal for unit of Canada's Therapure
04 Sep 2017 07:51 GMT
… a venture set up by 3SBio and CITIC Private Equity … the global market.
"3SBio's global expansion strategy … patients around the world."
3SBio, a major Chinese biopharmaceutical … oncology, auto-immune diseases and nephrology, will also get some …
-
Chinese biopharma 3SBio in $290 mln deal for unit of Canada's Therapure
04 Sep 2017 07:35 GMT
… venture set up by 3SBio and CITIC Private Equity … in the global market.
“3SBio’s global expansion strategy is … benefiting patients around the world.”
3SBio, a major Chinese biopharmaceutical … oncology, auto-immune diseases and nephrology, will also get some …
About
© 1995-2025